|  |  |
| --- | --- |
| **Pre-Program Assignments** | * **Pre-Lecture 1 - 2025 Viral Hepatitis Update –** A summary for discovery and natural history of viral hepatitis (25mins)
* **Pre-Lecture 2 - End Stage Liver Disease**: A systematic overview of Treatment, Managing Complications chronic liver disease, cirrhosis, and the transplant process (45 mins)
 |
| **7:30 am** | ***Registration and View Exhibits*** |
| **8:00 am** | **Opening Comments and Pre-Test** |
| **8:25 am** | **Hepatitis C-Elimination and Care for Special Populations**  * Recap the highlights of Pre-Lecture 1
* Viral Hepatitis Elimination - Caring for At-risk populations – homeless, PWID, the incarcerated, HIV-infected individuals
* Approved Direct Acting Antivirals
* The vital role of specialty pharmacy
* Clinical Cases and Discussion: HCV and At-Risk Individuals
* Overcoming the barriers to reinfection and linkages to care.
 |
| **9:05 am** | **Hepatitis B: Epidemiology, Natural History, Testing and Therapies** * Efficacies and opportunities in HBV testing and vaccination.
* Disease progression and impact on liver health
* The efficacy of HBV Vaccination
* Anti-viral therapies of HBV
* HBV Re-activation
* Latest studies from EASL and AASLD
 |
| **9:40 am** | **Delta Hepatitis and Hepatitis E Update** * Global and US perspective on the rapid growth of Delta Hepatitis
* Bulevirtide for Delta Hepatitis
* Testing and surveillance approaches
* Real world outcome studies on HDV and HEV
* Management of Chronic HEV
 |
| **10:15 am** | ***Disease Awareness Session – LAL-D, Break and View Exhibits*** |
| **11:00 am** | **End Stage Liver Disease: Recap and Clinical Cases** * A review of Pre-course lecture on end-stage liver disease
* Complications of cirrhosis
* Liver transplant in the era of DAA’s
* Clinical cases to illustrate HE. HRS and/or Thrombocytopenia
 |
| **11:30 am** | **Hepatocellular Carcinoma (HCC) - Disease Progression in the US*** Screening diagnostic serum assays and imaging tests
* Treatment and management options: Ablation, TACE and Surgery
* New studies showing cost effectiveness of surveillance post SVR
* PRIUS Study (MRI vs US) Abbreviated MRI
* 2024 AASLD screening guidance for liver cancer. New guidelines are less critical of liver biopsy for cancer detection
 |
| **12:00 pm** | **Hepatocellular Carcinoma: New Systemic Treatment Options** * **A case-based approach to HCC treatment**
* Promising 1st and 2nd line therapies for liver cancer
* New data on the benefit of downstaging
* New chemotherapy regimens in development and testing Immunotherapy as the new MoA for HCC
* Checkpoint inhibitors and VEGE inhibitors
 |
| **12:30 pm** | ***Lunch***  |
| **1:00 pm** | ***Dessert and View Exhibits*** |
| **1:15 pm** | **Cholestatic Liver Disease: Primary Biliary Cholangitis, Primary Sclerosing Cholangitis and Pruritus** * Epidemiology of PSC and Ursodiol and Antibiotic Treatments
* Predicting outcomes and Improving Survival in PSC patients
* Causes and Markers of PBC
* Coping with the clinical features of PBC
* Ursodeoxycholic Acid (UDCA) and Obetacholic Acid
* Highlights of the ELATIVE study on elafibranor and the ENHANCE study on seladelpar
* Understanding cholestatic pruritus and helping patients cope with the itching
 |
| **2:10 pm** | **Alcohol Associated Liver Disease** * The growing prevalence of alcohol over-consumption and its impact on liver health
* Alcohol consumption and malnutrition
* Warning signs and intervention in alcohol-associated hepatitis
* Promising therapeutic agents for AAH and other alcohol associated liver disease
 |
| ***2:45 pm*** | ***Break and Exhibits*** |
| **3:00 pm** | **Steatotic Liver Disease: The new healthcare epidemic** * New naming conventions for fatty liver disease: MASLD and MASH– what and why?
* Epidemiology, Demographics and Diagnosis
* Scoring, Staging and Management of Metabolic Liver Disease
* The ‘unhealthy” rise in MASLD in the US population and What can be done
* Treatment options for thrombocytopenia; including alternatives to platelet transfusion.
 |
| **3:40 pm** | **MASH Treatments in Practice and in Development** * Current therapies for NASH including Updates from AASLD and EASL
* Lifestyle changes as a therapy
* Drugs in clinical development for NASH – Semaglutide and Resmiteron
* MASH Diagnosis and Treatment case
 |
| **4:25 pm** | **Closing Comments, Post-test and Wrap-Up** Program adjourns at 4:45pm |
| **Post Program Lectures:** | **Lecture 3 - Fluid Management, Ascites and Hepatorenal Syndrome (**30 mins) **Lecture 4 – AASLD Update – Highlights of the 2024 AASLD Liver Meeting (**80 mins) |

**Course Director: Paul J. Pockros, MD - Scripps Health**